News
EMA starts rapid review of Bluebird’s gene therapy for rare ...
Bluebird bio could be just a few months away from approval of its gene therapy for rare disease cerebral adrenoleukodystrophy (CALD) in the EU, after the EMA started an accelerated review.<
